Cargando…
Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study
Autism spectrum disorder (ASD) is a pervasive neurodevelopmental disorder with repetitive behaviour which affects interaction and communication. Sulforaphane (SFN), an isothiocyanate abundant in the seeds and sprouts of cruciferous vegetables, has been shown to be effective in alleviating autistic b...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9920098/ https://www.ncbi.nlm.nih.gov/pubmed/36771424 http://dx.doi.org/10.3390/nu15030718 |
_version_ | 1784886987061198848 |
---|---|
author | Magner, Martin Thorová, Kateřina Župová, Veronika Houška, Milan Švandová, Ivana Novotná, Pavla Tříska, Jan Vrchotová, Naděžda Soural, Ivo Jílek, Ladislav |
author_facet | Magner, Martin Thorová, Kateřina Župová, Veronika Houška, Milan Švandová, Ivana Novotná, Pavla Tříska, Jan Vrchotová, Naděžda Soural, Ivo Jílek, Ladislav |
author_sort | Magner, Martin |
collection | PubMed |
description | Autism spectrum disorder (ASD) is a pervasive neurodevelopmental disorder with repetitive behaviour which affects interaction and communication. Sulforaphane (SFN), an isothiocyanate abundant in the seeds and sprouts of cruciferous vegetables, has been shown to be effective in alleviating autistic behaviour. We performed a prospective double-blind placebo-controlled study to examine the possible effect of SFN in a paediatric cohort aged three to seven years based on measurements of the Autism Diagnostic Observation Schedule-2 (ADOS-2), the Social Responsiveness Scale-2 (SRS-2), and the Aberrant Behaviour Checklist (ABC). The study consisted of three visits over the duration of 36 weeks (baseline, 18 weeks, and 36 weeks). Twenty-eight of the 40 randomized children completed the study. The mean total raw scores on ABC and SRS-2 improved in both groups, but none of the changes reached statistical significance (ABC: 0 weeks p = 0.2742, 18 weeks p = 0.4352, and 36 weeks 0.576; SRS-2: 0 weeks p = 0.5235, 18 weeks p = 0.9176, and 36 weeks 0.7435). Changes in the assessment of the ADOS-2 subscale scores also did not differ between the two study cohorts (ADOS-2: 0 weeks p = 0.8782, 18 weeks p = 0.4788, and 36 weeks 0.9414). We found no significant clinical improvement in the behavioural outcome measures evaluated in children with ASD aged 3–7 years that were treated with sulforaphane. |
format | Online Article Text |
id | pubmed-9920098 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99200982023-02-12 Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study Magner, Martin Thorová, Kateřina Župová, Veronika Houška, Milan Švandová, Ivana Novotná, Pavla Tříska, Jan Vrchotová, Naděžda Soural, Ivo Jílek, Ladislav Nutrients Article Autism spectrum disorder (ASD) is a pervasive neurodevelopmental disorder with repetitive behaviour which affects interaction and communication. Sulforaphane (SFN), an isothiocyanate abundant in the seeds and sprouts of cruciferous vegetables, has been shown to be effective in alleviating autistic behaviour. We performed a prospective double-blind placebo-controlled study to examine the possible effect of SFN in a paediatric cohort aged three to seven years based on measurements of the Autism Diagnostic Observation Schedule-2 (ADOS-2), the Social Responsiveness Scale-2 (SRS-2), and the Aberrant Behaviour Checklist (ABC). The study consisted of three visits over the duration of 36 weeks (baseline, 18 weeks, and 36 weeks). Twenty-eight of the 40 randomized children completed the study. The mean total raw scores on ABC and SRS-2 improved in both groups, but none of the changes reached statistical significance (ABC: 0 weeks p = 0.2742, 18 weeks p = 0.4352, and 36 weeks 0.576; SRS-2: 0 weeks p = 0.5235, 18 weeks p = 0.9176, and 36 weeks 0.7435). Changes in the assessment of the ADOS-2 subscale scores also did not differ between the two study cohorts (ADOS-2: 0 weeks p = 0.8782, 18 weeks p = 0.4788, and 36 weeks 0.9414). We found no significant clinical improvement in the behavioural outcome measures evaluated in children with ASD aged 3–7 years that were treated with sulforaphane. MDPI 2023-01-31 /pmc/articles/PMC9920098/ /pubmed/36771424 http://dx.doi.org/10.3390/nu15030718 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Magner, Martin Thorová, Kateřina Župová, Veronika Houška, Milan Švandová, Ivana Novotná, Pavla Tříska, Jan Vrchotová, Naděžda Soural, Ivo Jílek, Ladislav Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study |
title | Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study |
title_full | Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study |
title_fullStr | Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study |
title_full_unstemmed | Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study |
title_short | Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study |
title_sort | sulforaphane treatment in children with autism: a prospective randomized double-blind study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9920098/ https://www.ncbi.nlm.nih.gov/pubmed/36771424 http://dx.doi.org/10.3390/nu15030718 |
work_keys_str_mv | AT magnermartin sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy AT thorovakaterina sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy AT zupovaveronika sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy AT houskamilan sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy AT svandovaivana sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy AT novotnapavla sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy AT triskajan sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy AT vrchotovanadezda sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy AT souralivo sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy AT jilekladislav sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy |